Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine
Kåre I Birkeland, Philip D Home, Ulrich Wendisch, Robert E Ratner, Thue Johansen, Lars A Endahl, Karsten Lyby, Johan H Jendle, Anthony P Roberts, J Hans DeVries, Luigi F Meneghini, Kåre I Birkeland, Philip D Home, Ulrich Wendisch, Robert E Ratner, Thue Johansen, Lars A Endahl, Karsten Lyby, Johan H Jendle, Anthony P Roberts, J Hans DeVries, Luigi F Meneghini
Abstract
Objective: Insulin degludec (IDeg) is a basal insulin that forms soluble multihexamers after subcutaneous injection, resulting in an ultra-long action profile. We assessed the efficacy and safety of IDeg formulations administered once daily in combination with mealtime insulin aspart in people with type 1 diabetes.
Research design and methods: In this 16-week, randomized, open-label trial, participants (mean: 45.8 years old, A1C 8.4%, fasting plasma glucose [FPG] 9.9 mmol/L, BMI 26.9 kg/m(2)) received subcutaneous injections of IDeg(A) (600 μmol/L; n = 59), IDeg(B) (900 μmol/L; n = 60), or insulin glargine (IGlar; n = 59), all given once daily in the evening. Insulin aspart was administered at mealtimes. RESULTS At 16 weeks, mean A1C was comparable for IDeg(A) (7.8 ± 0.8%), IDeg(B) (8.0 ± 1.0%), and IGlar (7.6 ± 0.8%), as was FPG (8.3 ± 4.0, 8.3 ± 2.8, and 8.9 ± 3.5 mmol/L, respectively). Estimated mean rates of confirmed hypoglycemia were 28% lower for IDeg(A) compared with IGlar (rate ratio [RR]: 0.72 [95% CI 0.52-1.00]) and 10% lower for IDeg(B) compared with IGlar (RR: 0.90 [0.65-1.24]); rates of nocturnal hypoglycemia were 58% lower for IDeg(A) (RR: 0.42 [0.25-0.69]) and 29% lower for IDeg(B) (RR: 0.71 [0.44-1.16]). Mean total daily insulin dose was similar to baseline. The frequency and pattern of adverse events was similar between insulin treatments.
Conclusions: In this clinical exploratory phase 2 trial in people with type 1 diabetes, IDeg is safe and well tolerated and provides comparable glycemic control to IGlar at similar doses, with reduced rates of hypoglycemia.
Trial registration: ClinicalTrials.gov NCT00612040.
Figures
References
- The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–986
- Nathan DM, Cleary PA, Backlund JY, et al. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643–2653
- Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 2002;287:2563–2569
- The Diabetes Control and Complications Trial Research Group Hypoglycemia in the diabetes control and complications trial. Diabetes 1997;46:271–286
- Bartley PC, Bogoev M, Larsen J, Philotheou A. Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial. Diabet Med 2008;25:442–449
- Heise T, Nosek L, Rønn BB, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 2004;53:1614–1620
- Donnelly LA, Morris AD, Frier BM, et al. DARTS/MEMO Collaboration Frequency and predictors of hypoglycaemia in type 1 and insulin-treated type 2 diabetes: a population-based study. Diabet Med 2005;22:749–755
- Woodward A, Weston P, Casson IF, Gill GV. Nocturnal hypoglycaemia in type 1 diabetes—frequency and predictive factors. QJM 2009;102:603–607
- Cryer PE. The barrier of hypoglycemia in diabetes. Diabetes 2008;57:3169–3176
- Smith CB, Choudhary P, Pernet A, Hopkins D, Amiel SA. Hypoglycemia unawareness is associated with reduced adherence to therapeutic decisions in patients with type 1 diabetes: evidence from a clinical audit. Diabetes Care 2009;32:1196–1198
- Davis RE, Morrissey M, Peters JR, Wittrup-Jensen K, Kennedy-Martin T, Currie CJ. Impact of hypoglycaemia on quality of life and productivity in type 1 and type 2 diabetes. Curr Med Res Opin 2005;21:1477–1483
- Jonassen I, Havelund S, Ribel U, et al. Insulin degludec is a new generation ultra-long acting basal insulin with a unique mechanism of protraction based on multi-hexamer formation (Abstract). Diabetes 2010;59(Suppl. 1):A11
- World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects—Last amended by the 59th WMA General Assembly, Seoul 2008 [article online]. Available from Accessed 20 June 2008
- International Conference on Harmonisation. ICH Harmonised Tripartite Guideline: Guideline for Good Clinical Practice E6 (R1), Step 4 [article online]. Available from Accessed 20 June 2008
- Lindholm A, Jensen LB, Home PD, Raskin P, Boehm BO, Råstam J. Immune responses to insulin aspart and biphasic insulin aspart in people with type 1 and type 2 diabetes. Diabetes Care 2002;25:876–882
- Mire-Sluis AR, Barrett YC, Devanarayan V, et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods 2004;289:1–16
- Bulsara MK, Holman CD, Davis EA, Jones TW. Evaluating risk factors associated with severe hypoglycaemia in epidemiology studies—what method should we use? Diabet Med 2004;21:914–919
- Heise T, Hermanski L, Nosek L, et al. Insulin degludec: less pharmacodynamic variability than insulin glargine under steady state conditions (Abstract). Diabetologia 2010;53(Suppl. 1):S387
- Meneghini LF, Home PD, Wendisch U, et al. Insulin degludec, a new generation ultra-long acting insulin, in a mealtime + basal regimen in people with type 1 diabetes: comparison to insulin glargine (Abstract). Diabetes 2010;59(Suppl. 1):A152
- Meneghini LF, Home P, DeVries JH, et al. Insulin degludec, a new generation ultra-long acting insulin, in a mealtime + basal regimen in people with type 1 diabetes: comparison to insulin glargine (Abstract). Diabetologia 2010;53(Suppl. 1):S338
Source: PubMed